Trial Profile
Multicenter Prospective Cohort Study of the Hypoglycemic Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes: Triple Combination Therapy Using Metformin, Saxagliptin Plus Dapagliflozin Versus Premixed Insulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin (Primary) ; Saxagliptin (Primary) ; Insulin aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 14 Mar 2024 Status changed from not yet recruiting to completed.
- 16 Oct 2018 New trial record